Journal article
Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
The Journal of nuclear medicine (1978), Vol.64(7), pp.1001-1008
07/01/2023
DOI: 10.2967/jnumed.123.265594
PMID: 37268422
Abstract
Metastatic malignancies have limited management strategies and variable treatment responses. Cancer cells develop beside and depend on the complex tumor microenvironment. Cancer-associated fibroblasts, with their complex interaction with tumor and immune cells, are involved in various steps of tumorigenesis, such as growth, invasion, metastasis, and treatment resistance. Prooncogenic cancer-associated fibroblasts emerged as attractive therapeutic targets. However, clinical trials have achieved suboptimal success. Fibroblast activation protein (FAP) inhibitor–based molecular imaging has shown encouraging results in cancer diagnosis, making them innovative targets for FAP inhibitor–based radionuclide therapies. This review summarizes the results of preclinical and clinical FAP-based radionuclide therapies. We will describe advances and FAP molecule modification in this novel therapy, as well as its dosimetry, safety profile, and efficacy. This summary may guide future research directions and optimize clinical decision-making in this emerging field.
Details
- Title: Subtitle
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- Creators
- Manish Ora - Sanjay Gandhi Post Graduate Institute of Medical SciencesNeetu Soni - University of Rochester Medical CenterAftab Hasan Nazar - Sanjay Gandhi Post Graduate Institute of Medical SciencesManish Dixit - Sanjay Gandhi Post Graduate Institute of Medical SciencesRohit Singh - University of Vermont Medical CenterSavita Puri - University of Rochester Medical CenterMichael M Graham - University of IowaSanjay Gambhir - Sanjay Gandhi Post Graduate Institute of Medical Sciences
- Resource Type
- Journal article
- Publication Details
- The Journal of nuclear medicine (1978), Vol.64(7), pp.1001-1008
- DOI
- 10.2967/jnumed.123.265594
- PMID
- 37268422
- NLM abbreviation
- J Nucl Med
- eISSN
- 1535-5667
- Language
- English
- Electronic publication date
- 06/02/2023
- Date published
- 07/01/2023
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9984426745002771
Metrics
4 Record Views